Efficacy, safety, and exploratory biomarker analysis of rechallenge with immune checkpoint inhibitors combined with anlotinib in previously treated advanced non-small cell lung cancer.
[BACKGROUND] Immunotherapy is the standard treatment for driver-negative advanced non-small cell lung cancer (NSCLC), but resistance remains common.
APA
Liu L, Yang H, et al. (2026). Efficacy, safety, and exploratory biomarker analysis of rechallenge with immune checkpoint inhibitors combined with anlotinib in previously treated advanced non-small cell lung cancer.. BMC pulmonary medicine. https://doi.org/10.1186/s12890-025-04093-y
MLA
Liu L, et al.. "Efficacy, safety, and exploratory biomarker analysis of rechallenge with immune checkpoint inhibitors combined with anlotinib in previously treated advanced non-small cell lung cancer.." BMC pulmonary medicine, 2026.
PMID
41588364
Abstract
[BACKGROUND] Immunotherapy is the standard treatment for driver-negative advanced non-small cell lung cancer (NSCLC), but resistance remains common. Combining anti-angiogenic agents with immune checkpoint inhibitors (ICIs) may reverse resistance. This study evaluated the efficacy, safety, and optimal biomarkers of rechallenge with ICIs combined with anlotinib in advanced NSCLC patients previously treated with ICIs.
[METHODS] A total of 110 advanced NSCLC patients who progressed after prior ICI therapy were rechallenged with ICIs in combination with anlotinib. Primary endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and duration of response (DOR). Proteomics was performed on a subset of patients pre- and post-treatment to identify differentially expressed proteins. Patients were categorized into Responder (PFS ≥ 6 months) and Non-responder (PFS < 3 months) groups for proteomic comparison and functional validation of candidate proteins.
[RESULTS] Partial response (PR), stable disease (SD), and progressive disease (PD) were achieved in 20.9%, 57.3%, and 20.9% patients. ORR was 20.9% and disease control rate (DCR) was 78.2%, with median DOR of 7 months. Median PFS was 6.0 months and median OS was 16.0 months after rechallenge. Proteomic analysis revealed 91 significantly altered proteins post-treatment. ORM2 and SERPINA1 were hub proteins in the interaction network. External validation suggested a trend toward prolonged survival with high ORM2 and SERPINA1 expression.
[CONCLUSION] Rechallenge with ICIs plus anlotinib demonstrated encouraging efficacy and safety in pretreated advanced NSCLC. Additionally, ORM2 and SERPINA1 were associated with response and survival outcomes in patients treated with the combined ICI + anlotinib regimen and may represent candidate biomarkers of clinical benefit, warranting prospective validation.
[METHODS] A total of 110 advanced NSCLC patients who progressed after prior ICI therapy were rechallenged with ICIs in combination with anlotinib. Primary endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and duration of response (DOR). Proteomics was performed on a subset of patients pre- and post-treatment to identify differentially expressed proteins. Patients were categorized into Responder (PFS ≥ 6 months) and Non-responder (PFS < 3 months) groups for proteomic comparison and functional validation of candidate proteins.
[RESULTS] Partial response (PR), stable disease (SD), and progressive disease (PD) were achieved in 20.9%, 57.3%, and 20.9% patients. ORR was 20.9% and disease control rate (DCR) was 78.2%, with median DOR of 7 months. Median PFS was 6.0 months and median OS was 16.0 months after rechallenge. Proteomic analysis revealed 91 significantly altered proteins post-treatment. ORM2 and SERPINA1 were hub proteins in the interaction network. External validation suggested a trend toward prolonged survival with high ORM2 and SERPINA1 expression.
[CONCLUSION] Rechallenge with ICIs plus anlotinib demonstrated encouraging efficacy and safety in pretreated advanced NSCLC. Additionally, ORM2 and SERPINA1 were associated with response and survival outcomes in patients treated with the combined ICI + anlotinib regimen and may represent candidate biomarkers of clinical benefit, warranting prospective validation.
같은 제1저자의 인용 많은 논문 (5)
- Augmentation of the Nasal Dorsum Using the Multistrip Autologous Cartilage Technique.
- Short-term outcome of totally laparoscopic gastrectomy for gastric cancer: a comparative study.
- A Predictive Model Study on Differentiating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound, Shear Wave Elastography, and Clinical Feature-Based Nomogram.
- Research Trends and Development Dynamics of qPCR-based Biomarkers: A Comprehensive Bibliometric Analysis.
- Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients.